<DOC>
	<DOCNO>NCT02360943</DOCNO>
	<brief_summary>The treatment venous thromboembolic disease , include pulmonary embolism ( PE ) , base anticoagulant . During last decade , randomize clinical trial evaluate anticoagulant include PE patient average age 60 year . But clinical pratice , approximately 50 % PE patient older 75 year . So investigators want perform french multicentre prospective cohort consecutive patient receive anticoagulant treatment symptomatic confirm PE . All validate available anticoagulant treatment authorize cohort ( unfractionnated low molecular weight heparin , fondaparinux , vitamin K antagonist direct oral anticoagulant ) . This cohort provide data regard bleeding risk risk PE recurrences regard pharmacokinetic ( PK ) pharmacodynamic ( PD ) property anticoagulant old population . Using population approach modelling , investigator pay particular attention source PK/PD variability PK / PD genetic polymorphism P-glycoprotein cytochrome P450 . Using data , investigator try identify significant risk factor bleed venous thromboembolic event .</brief_summary>
	<brief_title>Pharmacoepidemiology Treatment Symptomatic Pulmonary Embolism Hospitalized Patients Aged 75 Years More : PEAGE</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Symptomatic pulmonary embolism confirm objective paraclinical examination without DVT associate confirmation pulmonary embolism within 3 day Administration possible accord recommended dosage anticoagulant treatment : ( unfractionnated low molecular weight heparin , fondaparinux , vitamin K antagonist direct oral anticoagulant ) Indication anticoagulant treatment least 6 month therapeutic dose anticoagulant treatment 72 hour indication therapeutic dose anticoagulant treatment another reason . Inability whatever reason , prescribe recommend anticoagulant treatment PE treatment heparininduced thrombocytopenia require argatroban , lepirudin danaparoid treatment , ongoing bleed PE occur despite well conduct anticoagulant treatment Contraindications recommend dose anticoagulant treatment</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>elderly patient</keyword>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Anticoagulant treatment</keyword>
</DOC>